Study Group For 25 High-Risk Items In August, Law Reform In Sight
This article was originally published in PharmAsia News
Executive Summary
After the Japanese government decided to lift the ban on Internet generic drug sales, MHLW has decided to set up a study group in August to decide how to sell 25 drugs considered as high risk items, stated Pharmaceutical and Food Director Toshio Imabeppu in his first specialist paper since taking office.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.